ELOX · Eloxx Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $510.0K | - | - | - | $1.25M | $2.34M | $3.49M | - | $4.88M | $7.65M |
| SG&A | $712.0K | - | - | - | $2.39M | $1.80M | $2.00M | - | $2.26M | $2.65M |
| Total Operating Expenses | $3.79M | - | - | - | $3.64M | $4.14M | $5.48M | - | $7.14M | $10.30M |
| D&A | - | - | - | - | - | - | $15.0K | - | $23.0K | $22.0K |
| Operating Income | ($1.22M) | - | - | - | ($3.64M) | ($4.14M) | ($5.48M) | - | ($7.14M) | ($10.30M) |
| Interest Expense | $500.0K | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.75M) | - | - | - | ($3.59M) | ($4.34M) | ($6.23M) | - | ($7.51M) | ($10.62M) |
| EPS - Basic | ($0.08) | - | - | - | ($1.31) | ($1.96) | ($5.36) | - | ($0.09) | ($0.54) |
| EPS - Diluted | ($0.45) | - | - | - | ($1.31) | ($1.96) | ($2.88) | - | ($0.11) | ($0.54) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $450.0K | $4.79M | $111.0K | $1.13M | $4.78M | $4.33M | $4.90M | $19.21M | $24.55M | $30.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.03M | $2.71M | $5.35M | $5.70M | $3.13M | $3.12M | $2.43M | $3.02M | $1.59M | $1.93M |
| Current Assets | $8.50M | $5.27M | $2.98M | $1.55M | $5.63M | $5.38M | $6.40M | $20.13M | $25.67M | $31.59M |
| Total Assets | $8.50M | $5.27M | $2.98M | $1.71M | $6.04M | $5.99M | $7.20M | $21.12M | $26.88M | $32.94M |
| Current Liabilities | $16.09M | $17.18M | $27.31M | $22.70M | $23.47M | $21.25M | $19.46M | $23.09M | $21.68M | $19.50M |
| Long-term Debt | - | $0 | $0 | $1.61M | $2.62M | $3.33M | $4.03M | $8.56M | $9.86M | $11.13M |
| Total Liabilities | - | $17.18M | $27.31M | $24.31M | $26.09M | $24.59M | $23.49M | $31.78M | $31.86M | $31.13M |
| Stockholders' Equity | ($7.58M) | ($11.91M) | ($24.34M) | ($22.60M) | ($20.05M) | ($18.60M) | ($16.29M) | ($10.66M) | ($4.98M) | $1.81M |
| Retained Earnings | ($304.33M) | ($300.58M) | ($294.58M) | ($291.44M) | ($288.55M) | ($284.96M) | ($280.62M) | ($274.39M) | ($268.07M) | ($260.56M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.45M) | - | - | - | - | - | ($6.81M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | $11.0K | - | - | - |
| Financing Cash Flow | ($865.0K) | - | - | - | - | - | ($7.50M) | - | - | - |
| CapEx | - | - | - | - | - | - | $0 | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($6.81M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.09 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -44.1% | - | - | - | -59.5% | -72.4% | -86.5% | - | -27.9% | -32.2% |
| Return on equity | 49.5% | - | - | - | 17.9% | 23.3% | 38.2% | - | 150.7% | -586.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.53 | 0.31 | 0.11 | 0.07 | 0.24 | 0.25 | 0.33 | 0.87 | 1.18 | 1.62 |
| Quick ratio | 0.53 | 0.31 | 0.11 | 0.07 | 0.24 | 0.25 | 0.33 | 0.87 | 1.18 | 1.62 |
| Cash ratio | 0.03 | 0.28 | 0.00 | 0.05 | 0.20 | 0.20 | 0.25 | 0.83 | 1.13 | 1.54 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.00 | 0.00 | -0.07 | -0.13 | -0.18 | -0.25 | -0.80 | -1.98 | 6.14 |
| Debt / Assets | - | 0.00 | 0.00 | 0.94 | 0.43 | 0.56 | 0.56 | 0.41 | 0.37 | 0.34 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2.4x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.12 | -0.44 | -0.12 | -0.08 | -0.30 | -0.32 | -0.44 | -1.98 | -5.40 | 18.18 |
| Liabilities / Assets | - | 3.26 | 9.18 | 14.20 | 4.32 | 4.10 | 3.26 | 1.50 | 1.19 | 0.94 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | 49.1% | 59.8% | 49.9% | - | 30.3% | 71.2% |
| Net income growth (YoY) | - | - | - | - | 52.2% | 59.1% | 46.4% | - | 24.0% | 70.6% |
| EPS growth (YoY) | - | - | - | - | -1090.9% | -263.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 28.3% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 51.1% | -7.7% | -112.0% | -302.4% | - | - | - | - | -95.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Eloxx Pharmaceuticals against the 5 most active filers in the same SIC group.